| Original language | English |
|---|---|
| Pages (from-to) | E157-E176 |
| Journal | Journal of the Canadian Urological Association |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2019 |
Bibliographical note
Funding Information:Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs, and has received a research grant from Astellas. Dr. Baverstock has been a speaker for Allergan, Astellas, BSCI, and Pfizer; and has participated in clinical trials supported by Astellas and Pfizer. Dr. Campeau has been an advisory board and speaker bureau member for Asetllas and Pfizer; has received grants/honoraria from Allergan, Astellas, and Pfizer; and has participated in clinical trials supported by Pfizer. Dr. Cox has been an advisory board member for Pfizer; a speakers bureau member for Astellas and Pfizer; has received grants/honoraria from Astellas and Pfizer; and has participated in clinical trials supported by Aquinox. Dr. Hickling has been an advisory board member for Pfizer; a speakers bureau member for Allergan, Astellas and Pfizer; has received grants/honoraria from Allergan, Astellas and Pfizer; and has participated in clinical trials supported by Astellas. Dr. Nadeau has been an advisory board member for Allergan, AMS, Astellas, Boston Scientific, Ferring, and Pfizer; a speakers bureau member for, Allergan, Astellas, Ferring Laborie, and Pfizer; and and has participated in clinical trials supported by Astellas. The remaining authors report no competing personal or financial interests related to this work.
ASJC Scopus Subject Areas
- Oncology
- Urology
PubMed: MeSH publication types
- Journal Article